文章：

早期舌鳞状细胞癌前哨淋巴结活检（SLNB）：意大利国家肿瘤研究所“G.Pascale”二十年经验总结

Sentinel Lymph Node Biopsy (SLNB) for Early-Stage Head and Neck Squamous-Cell Carcinoma of the Tongue: Twenty Years of Experience at I.N.T. “G.Pascale”

原文发布日期：14 March 2024

DOI: 10.3390/cancers16061153

类型: Article

开放获取: 是

英文摘要：

Oral tongue squamous-cell carcinoma (OTSCC) is the most prevalent malignancy in the head and neck region. Lymphatic spread, particularly to cervical lymph nodes, significantly impacts 5-year survival rates, emphasizing the criticality of precise staging. Metastatic cervical lymph nodes can decrease survival rates by 50%. Yet, elective neck dissection (END) in T1–2 cN0 patients proves to be an overtreatment in around 80% of cases. To address this, sentinel lymph node biopsy (SLNB) was introduced, aiming to minimize postoperative morbidity. This study, conducted at the ENT and Maxillofacial Surgery department of the Istituto Nazionale Tumori in Naples, explores SLNB’s efficacy in early-stage oral tongue squamous-cell carcinoma (OTSCC). From January 2020 to January 2022, 122 T1/T2 cN0 HNSCC patients were enrolled. Radioactive tracers and lymphoscintigraphy identified sentinel lymph nodes, aided by a gamma probe during surgery. Results revealed 24.6% SLN biopsy positivity, with 169 SLNs resected and a 21.9% positivity ratio. The study suggests SLNB’s reliability for T1-2 cN0 OTSCC patient staging and early micrometastasis detection.

摘要翻译： 

口腔舌鳞状细胞癌是头颈部最常见的恶性肿瘤。淋巴转移，尤其是向颈部淋巴结的扩散，显著影响患者五年生存率，这凸显了精确分期的重要性。颈部淋巴结转移可使生存率降低50%。然而，对于T1-2 cN0期患者，选择性颈淋巴结清扫术在约80%的病例中被证实属于过度治疗。为解决这一问题，前哨淋巴结活检技术应运而生，旨在降低术后并发症发生率。本研究在那不勒斯国家肿瘤研究所耳鼻喉与颌面外科开展，旨在探讨前哨淋巴结活检在早期口腔舌鳞状细胞癌诊疗中的有效性。2020年1月至2022年1月期间，共纳入122例T1/T2 cN0期头颈鳞癌患者。通过放射性示踪剂和淋巴显像技术定位前哨淋巴结，术中辅以伽马探针检测。结果显示前哨淋巴结活检阳性率为24.6%，共切除169枚前哨淋巴结，阳性比例为21.9%。研究表明，前哨淋巴结活检对于T1-2 cN0期口腔舌鳞状细胞癌患者的分期及早期微转移检测具有可靠性。

原文链接：

Sentinel Lymph Node Biopsy (SLNB) for Early-Stage Head and Neck Squamous-Cell Carcinoma of the Tongue: Twenty Years of Experience at I.N.T. “G.Pascale”